[Form 4] Xeris Biopharma Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insider sale of XERS common stock reduced holdings: Director John Johnson sold 107,500 shares of Xeris Biopharma common stock on 08/13/2025 at a weighted average price of $7.3159 per share, leaving him with 833,483 shares beneficially owned. The Form 4 lists the sale as a direct disposition and notes the reported price is a weighted average reflecting multiple trades priced between $7.250 and $7.420. No derivative transactions or additional changes in indirect ownership are reported. The filing was signed by an attorney-in-fact on behalf of the reporting person.

Positive

• None.

Negative

• Director John Johnson executed a direct sale of 107,500 XERS shares, reducing his beneficial ownership to 833,483 shares.
• The sale may represent insider liquidity; the filing does not state a Rule 10b5-1 plan or other rationale for the disposition.

Insights

Financial Analyst

TL;DR: A director sold 107,500 XERS shares at ~$7.32, reducing direct holdings to 833,483 shares.

The sale is a straightforward, non-derivative disposition reported under Section 16. The transaction was executed in multiple trades at prices between $7.25 and $7.42, producing a weighted average price of $7.3159. Without concurrent disclosure of intentions, planned Rule 10b5-1 activity, or size relative to outstanding shares, this single reported sale is a data point rather than definitive evidence of material change in company outlook. Investors should view this as routine insider liquidity unless corroborated by additional filings or company events.

Corporate Governance Expert

TL;DR: Director-reported sale is properly disclosed; documentation notes weighted-average pricing across multiple trades.

The Form 4 correctly identifies the reporting person as a director and records a direct disposition. The explanation clarifies the weighted-average price range and offers to provide transaction-level pricing on request, which supports disclosure transparency. There is no indication in the filing of an amendment, a Section 16 exemption, or a Rule 10b5-1 plan election tied to this sale. From a governance compliance standpoint, the filing meets Section 16 reporting requirements as presented.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JOHNSON JOHN

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO IL 60607

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2025		S		107,500	D	$7.3159(1)	833,483	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.250 to $7.420, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ Beth Hecht, Attorney-in-Fact	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the XERS Form 4 filed for John Johnson report?

The Form 4 reports a direct sale of 107,500 Xeris Biopharma (XERS) common shares executed on 08/13/2025 at a weighted average price of $7.3159, leaving 833,483 shares beneficially owned.

At what prices were the XERS shares sold according to the filing?

The filing states the shares were sold in multiple transactions at prices ranging from $7.250 to $7.420, producing a weighted average of $7.3159.

Was the sale reported as direct or indirect on the XERS Form 4?

The transaction is reported as a direct disposition by the reporting person.

Does the Form 4 indicate any derivative transactions for XERS by this reporting person?

No. The filing contains no entries in Table II for derivative securities; only a non-derivative common stock sale is reported.

Who signed the Form 4 for the reporting person?

The Form 4 was signed on behalf of the reporting person by an attorney-in-fact, Beth Hecht, as indicated in the signature block.